Virios Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on Thursday, August 12, 2021Business Wire • 08/05/21
Virios Therapeutics Highlights Clinical Sites Fully Operational in Phase 2b Fibromyalgia Study Featuring FDA “Fast Track” Review Designated Antiviral Therapy, Oral IMC-1Business Wire • 07/26/21
Virios Therapeutics Stock Moves Higher On Promising IMC-1 Safety Data In Mid-Stage Fibromyalgia TrialBenzinga • 06/09/21
Virios Therapeutics Highlights Safety Data from Phase 2a Fibromyalgia Trial at the International Association for the Study of Pain (IASP) World CongressBusiness Wire • 06/09/21
Virios Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating IMC-1 in Patients with FibromyalgiaBusiness Wire • 06/04/21
Virios Therapeutics Presents Phase 2a Fibromyalgia Trial Data on Efficacy Analyses of Key Secondary Endpoints at the EULAR European Congress of RheumatologyBusiness Wire • 06/02/21
Virios Therapeutics Announces Oral Presentation of Clinical Data at Digestive Disease Week® (DDW)Business Wire • 05/24/21
Virios Therapeutics, Inc. (VIRI) CEO Greg Duncan on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/13/21
Virios Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate UpdateBusiness Wire • 05/13/21
Virios Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update on Thursday, May 13, 2021Business Wire • 05/06/21
Virios Therapeutics, Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money ReportBusiness Wire • 04/16/21
Virios Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate UpdateBusiness Wire • 03/18/21
Virios Therapeutics: Highly Differentiated Mechanism Of Action In FibromyalgiaSeeking Alpha • 03/15/21
Virios Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Thursday, March 18, 2021Business Wire • 03/11/21
Virios Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference in March 2021Business Wire • 02/24/21
Virios Therapeutics, Inc. Announces Research Collaboration to Explore Role of HSV-1 in Irritable Bowel SyndromeBusiness Wire • 02/01/21
Virios Therapeutics to Present at the H.C. Wainwright Virtual BioConnect ConferenceBusiness Wire • 01/04/21
Virios Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Over-Allotment OptionBusiness Wire • 12/21/20